SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001068238-20-000020
Filing Date
2020-01-24
Accepted
2020-01-24 16:09:12
Documents
1
Group Members
BAYER AG

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D/A crispr_sch13da.htm SC 13D/A 91596
  Complete submission text file 0001068238-20-000020.txt   93135
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Subject) CIK: 0001674416 (see all company filings)

IRS No.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89674 | Film No.: 20545555
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O CRISPR THERAPEUTICS AG 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address C/O CRISPR THERAPEUTICS AG 200 SIDNEY STREET CAMBRIDGE MA 02139 617-315-4600
Bayer Global Investments B.V. (Filed by) CIK: 0001685417 (see all company filings)

IRS No.: 000000000 | State of Incorp.: XX | Fiscal Year End: 1231
Type: SC 13D/A